Hepatology & Hepatitis CME

Target Audience: Physicians focusing on Infectious Diseases. 

In-depth CME Review of Gastrointestinal Diseases

Gastroenterology and Hepatology Board Review is an online video CME program covering normal function, signs, symptoms, and diseases of the gastrointestinal organs — from the esophagus and stomach to the small intestine, colon, liver, pancreas, and biliary tract.

This continuing medical education program includes 40+ one-hour lectures delivered by recognized experts with extensive clinical experience. You’ll benefit from the decision-making expertise of these skilled educators as they discuss diagnostic procedures, medical therapy, surgical therapy, and procedural therapy. Presentations combine scientific evidence and clinical judgment, culminating with recommendations for the most appropriate care and improved patient outcomes.

The management of critically ill patients with liver disease requires the expertise of a variety of healthcare providers from multiple disciplines. Cleveland Clinic addresses their multifaceted educational needs with the Interprofessional Approach to Liver Disease. Physicians, nurses and physician assistants will benefit from the latest strategies and evidence based management guidance from an expert faculty. Worth 14 AMA PRA Category I Credits™, with ANCC and AAPA accreditation provided as well. This enduring material also qualifies for 14 ABIM MOC points, with NO POST TEST.

Activity Description / Statement of Need:

In this online, self-learning activity:

Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, with the accumulation of fat in the liver in excess of five percent of the liver’s weight, together with hepatic inflammation in the presence or absence of fibrosis. Risk factors for NASH include a number of comorbid metabolic diseases and disorders, including metabolic syndrome, obesity, type 2 diabetes, hypertension, and dyslipidemia. The prevalence of NASH is estimated to be 1.5%-6.45% of the U.S. population, and prevalence of NASH among NAFLD patients to be 59.1% globally.

Target Audience:

The following HCPs in: Gastroenterology, hepatology, and endocrinology; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with NAFLD.